Amgen 2001 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2001 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 54

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54

While potential new treatments for
cancer are being studied in thousands
of global research settings, including
Amgen’s oncology research program,
chemotherapy remains one of the most
widely chosen treatment options for
many types of cancer.
Unfortunately, chemotherapy can have
side effects–among them neutropenia,
a decline in the number of neutrophils,
the infection-fighting white blood cells.
For more than a decade, Amgen has
helped cancer patients undergoing myelo-
suppressive chemotherapy combat neu-
tropenia with NEUPOGEN
®
(Filgrastim).
This groundbreaking therapeutic is a
recombinant form of a naturally occur-
ring human protein that stimulates the
production of neutrophils.
NEUPOGEN
®
is approved for use in
98 countries. Since its introduction
in 1991, NEUPOGEN
®
has helped an
estimated 3.5 million cancer patients
tolerate their prescribed doses of
chemotherapy treatment by reducing
the incidence of costly and sometimes
life-threatening infections.
Amgen supports a number of programs
in conjunction with the oncology health
care community to help optimize the
benefits of NEUPOGEN
®
. These include
data collection to assist oncologists by
providing better information on the
use of chemotherapy and NEUPOGEN
®
,
as well as feedback on patient outcomes.
This information has been particularly
useful in helping physicians optimize
treatment alternatives in the most cost-
efficient manner.
Amgen last year submitted
filings with regulatory
authorities in the United States,
Europe, Canada, Australia, and
New Zealand for the use of
Amgen’s newest anemia
therapeutic, Aranesp
™
, in the
treatment of chemotherapy-
induced anemia.
Neulasta
™
, Amgen’s new
white blood cell booster,
received U.S. regulatory
approval early this year for
use in preventing the potential
complications of infection in
the chemotherapy setting.
14